Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Am J Kidney Dis ; 50(5): 821-5, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17954295

ABSTRACT

Several drugs, including hydralazine and propylthiouracil, can induce antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. d-Penicillamine was implicated in a few patients with rheumatoid arthritis or systemic sclerosis, but in patients with both diseases, ANCA-associated vasculitides were described in the absence of the drug. Therefore, the role of d-penicillamine treatment could not be established. We report the first case of antimyeloperoxidase antibody-associated vasculitis in a patient treated with d-penicillamine for Wilson disease. Because Wilson disease was never associated with ANCA-related nephritis, this case strongly supports that d-penicillamine can induce ANCA-vasculitis. The presentation and rapidly progressive and potentially severe outcome of this complication dramatically contrast with those of membranous and minimal change glomerulopathy, also induced by the sulfhydryl compound.


Subject(s)
Antibodies, Antineutrophil Cytoplasmic/blood , Chelating Agents/adverse effects , Glomerulonephritis/chemically induced , Hepatolenticular Degeneration/drug therapy , Penicillamine/adverse effects , Vasculitis/chemically induced , Adult , Chelating Agents/therapeutic use , Creatinine/blood , Disease Progression , Female , Glomerulonephritis/immunology , Glomerulonephritis/pathology , Glucocorticoids/administration & dosage , Humans , Kidney Function Tests , Kidney Glomerulus/pathology , Methylprednisolone/administration & dosage , Necrosis , Penicillamine/therapeutic use , Peroxidase/immunology , Vasculitis/immunology
3.
Nephrol Dial Transplant ; 21(4): 1032-9, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16364990

ABSTRACT

BACKGROUND: The clinical determinants of baseline peritoneal membrane (PM) transport characteristics, as evaluated by a hypertonic peritoneal equilibration test (PET), remain ill-defined. Likewise, the longitudinal evolution of PM transport properties in peritoneal dialysis (PD) patients given automated PD (APD) and icodextrin still needs to be determined precisely. The aims of the present study were (1) to determine the clinical and biological factors affecting PM transport characteristics at PD onset and (2) to assess the longitudinal evolution of these markers. METHODS: Seventy-two consecutive patients performed a baseline 3.86% glucose dialysate PET and were enrolled. Subgroups of 35 and 18 patients underwent another PET 1 and 2 year(s) later, respectively, and were included in the longitudinal part. For each patient, clinical and biological data were reviewed and PM transport markers calculated. RESULTS: At onset of PD, angiotensin-converting enzyme (ACE) inhibitor intake (r = 0.31, P = 0.01), presence of a diabetes (r = 0.26, P = 0.03) and body surface area (BSA) (r = 0.26, P = 0.03) independently affected the mass transfer area coefficient (MTAC) of creatinine. Serum albumin (r = -0.46, P<0.001) and net ultrafiltration (r = -0.33, P = 0.009) inversely correlated with MTAC creatinine. Sodium sieving was inversely correlated with BSA (r = -0.33, P = 0.01). Serum albumin also inversely correlated with albumin clearance (r = -0.39, P = 0.02). Finally, the independent covariates that affected alpha2-macroglobulin clearance were age (P = 0.03), diabetes (P = 0.01) and the level of residual renal function (P<0.01). Serum albumin decreased with time on PD (P = 0.02). A rise in small solute transport and a decrease in net ultrafiltration, but no change in protein clearances, were also observed after 2 years of PD. CONCLUSIONS: Transport properties across the PM, as evaluated by MTAC creatinine and sodium sieving determinations, are correlated with anthropometric characteristics (BSA) and by comorbid conditions (witnessed by the presence of diabetes, a low serum albumin concentration and the prescription of an ACE inhibitor). The short-term evolution (2 years) of the PM transport properties of patients on APD and icodextrin is still characterized by a progressive increase in small solute transport and a loss of ultrafiltration capacity, as documented in ancient studies, but not with a modification in protein clearances. This conclusion merits, however, to be further evaluated in a larger cohort of PD patients after a longer follow-up.


Subject(s)
Peritoneal Dialysis , Peritoneum/metabolism , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biological Transport , Body Surface Area , Creatinine/metabolism , Female , Follow-Up Studies , Humans , Kidney Function Tests , Longitudinal Studies , Male , Metabolic Clearance Rate , Middle Aged , Serum Albumin/analysis , Ultrafiltration , alpha-Macroglobulins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...